Equities Analysts Set Expectations for ANIX Q1 Earnings

Anixa Biosciences, Inc. (NASDAQ:ANIX) – Equities researchers at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Anixa Biosciences in a research report issued on Tuesday, February 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.11). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.41) EPS.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02.

Separately, D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, January 22nd.

Anixa Biosciences Stock Down 2.8 %

ANIX stock opened at $3.08 on Friday. The business has a 50 day moving average price of $2.71 and a two-hundred day moving average price of $3.05. The company has a market cap of $99.18 million, a price-to-earnings ratio of -7.90 and a beta of 0.93. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in Anixa Biosciences by 36.5% in the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Virtu Financial LLC bought a new stake in Anixa Biosciences in the 3rd quarter valued at $34,000. Millennium Management LLC bought a new stake in Anixa Biosciences in the 4th quarter valued at $26,000. LPL Financial LLC boosted its stake in Anixa Biosciences by 37.2% in the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after purchasing an additional 11,633 shares during the period. Finally, Tyler Stone Wealth Management boosted its stake in Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Insider Transactions at Anixa Biosciences

In other news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, January 17th. The stock was acquired at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the purchase, the director now directly owns 922,334 shares of the company’s stock, valued at $2,370,398.38. This trade represents a 1.10 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Amit Kumar purchased 43,000 shares of Anixa Biosciences stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average price of $2.23 per share, with a total value of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 75,289 shares of company stock worth $177,021. 25.30% of the stock is owned by company insiders.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.